期刊文献+

儿童Ⅲ期神经母细胞瘤的临床观察 被引量:3

Therapeutic experience of childhood stage Ⅲ neuroblastoma
原文传递
导出
摘要 目的 分析儿童Ⅲ期神经母细胞瘤(NB)的诊治方案、远期疗效及影响预后因素.方法 回顾性分析1999年1月至2007年5月在我院初诊并接受NB-99方案治疗和随访的Ⅲ期NB患儿.结果 在101例NB患儿中,Ⅲ期患儿30例,占29.7%,其中男性患儿19例,女性患儿11例.诊断时年龄(33±30)个月.原发部位以腹部和后纵隔多见,分别为16例和10例.病理分型为预后良好型者21例.11例患儿进入中危组治疗;6例患儿在化疗后行自体造血干细胞移植;5例在化疗后未接受维甲酸治疗.随访期5-96个月,中位随访时间43个月.28例患儿在治疗中达完全缓解,有7例出现复发,总的无事件生存率和存活率分别达74%±9%和77%±8%.单因素分析显示初诊时病理分型、乳酸脱氢酶(LDH)水平、血清铁蛋白(SF)水平和是否进行维甲酸治疗与Ⅲ期NB患儿的预后相关(X2=9.48、6.82、9.17、9.06,均P〈0.05);多因素分析显示LDH、SF、维甲酸治疗和干细胞移植与预后相关(OR=3.95、3.44、2.64、1.27,均P〈0.05).结论 儿童Ⅲ期NB疗效受LDH、SF、维甲酸治疗和干细胞移植等因素影响. Objective To evaluate the long-term outcomes of childhood stage Ⅲ neuroblastoma (NB) and its associated prognostic factors.Methods Children with newly diagnosed NB were enrolled into the protocol of NB-99 and followed up from January 1999 to May 2007.The relevant data were collected.And the statistics was processed by SPSS 10.0.Results Thirty children with stage ill NB were found among all 101 children with NB.There were 19 males and 11 females.The mean age at diagnosis was (33±30) months.Abdomen and thorax were by far the most common sites of primary tumor (16 and 10 respectively).Twenty-one NB children had favorable pathology classification Eleven NB children were treated according to the mediate-risk protocol,6 children received autologous stem cell transplantation (ASCT) after chemotherapy and 5 patients had no therapy of cis-retinoic acid.Follow-up was conducted for 5-96 months.A complete response or an excellent partial remission was observed in 28 patients.Seven patients relapsed or progressed at the primary tumor site or bone marrow.The estimated cumulative probabilities of event-free survival and overall survival at 4 years for these 30 patients were 74%±9% and 77%±8% respectively.On univariate analysis,pathological type,high levels of LDH and ferritin,non-therapy of cis-retinoic acid were associated with a worse survival (X2=9.48,6.82,9.17,9.06,all P〈0.05).As to the multivariate estimates of hazards ratio,high levels of LDH and ferritin,no ASCT and non-therapy of cis-retinoic acid were associated with a worse survival (OR=3.95,3.44,2.64,1.27,all P〈0.05).Conclusion Stage Ⅲ NB children with favorable histologic features,normal LDH,normal serum ferritin,receive ASCT,and treated with cis-retinoic acid have a lower risk of relapse.
出处 《中华医学杂志》 CAS CSCD 北大核心 2010年第22期1556-1558,共3页 National Medical Journal of China
基金 上海市科学技术委员会重点科技支撑计划(08411953700)
关键词 神经母细胞瘤 儿童 预后 Neuroblastoma Child Prognosis
  • 相关文献

参考文献8

  • 1Mans JM,Hogarty MD,Bagatell R,et al.Neuroblastoma.Lancet,2007,369:2106-2120. 被引量:1
  • 2汤静燕,潘慈,刘茵,徐敏,薛惠良,陈静,董璐,周敏,顾龙君.儿童Ⅳ期神经母细胞瘤远期随访报告[J].中国小儿血液与肿瘤杂志,2009,14(2):66-70. 被引量:10
  • 3Monclair T,Brodeur GM,Ambros PF,et al.The international neuroblastoma risk group (INRC) staging system:an INRG task force report.J Clin Oncol,2009,27:298-303. 被引量:1
  • 4Park JR,Villablanca JG,London WB,et al.Outcome of highrisk stage 3 neuroblastoma with myeloablative therapy and 13-cisretinoic acid; a report from the Children' s Oncology Group.Pediatr Blood Cancer,2009,52:44-50. 被引量:1
  • 5Matthay KK,Quach A,Huberty J,et al.Iodine-131metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma:a new approaches to neuroblastoma therapy phase I study.J Clin Oncol,2009,27:1020-1025. 被引量:1
  • 6Canete A,Gerrard M,Rubie H,et al.Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment:the international society of paediatric oncology european neuroblastoma experience.J Clin Oncol,2009,27:1014-1019. 被引量:1
  • 7Modak S,Kushner BH,LaQuaglia MP,et al.Management and outcome of stage 3 neuroblastoma.Eur J Cancer,2009,45:90-98. 被引量:1
  • 8Wagner LM,Villablanca JG,Stewart CF,et al.Phase I trial of oral irinotecan and temozolomide for children with relapsed highrisk neuroblastoma:a new approach to neuroblastoma therapy consortium study.J Clin Oncol,2009,27:1290-1296. 被引量:1

二级参考文献16

  • 1Brodeur GM, Seeger RC, Barrett A, et al. Intemational criteria for diagnosis, staging, and response to treatment. J Clin Oncol, 1993 ; 11 : 1466-1477. 被引量:1
  • 2London WB, Boni L, Simon T, et al. The role of age in neuroblastoma risk stratification : the German, Italian, and children' s oncology group perspectives. Cancer Lett,2005 ;228(1-2) :257-266. 被引量:1
  • 3Pearson AD, Pinkerton CR, Lewis IJ, ET AL. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol, 2008 Mar;9 (3) :247-256. 被引量:1
  • 4Valteau-Couanet D, Michon J, Boneu A, et al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol, 2005 Jan 20 ;23 (3) : 532-540. 被引量:1
  • 5Frappaz D, Michon J, Coze C, et al: LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol,2000;18:468-476. 被引量:1
  • 6Kaneko M, Tsuchida Y, Mugishima H,et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol, 2002 Nov;24(8) : 613-621. 被引量:1
  • 7McGregor LM, Rao BN, Davidoff AM et al. The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children' s Research Hospital Experience. Cancer, 2005; 104 (12): 2837-2846. 被引量:1
  • 8Sung KW, Lee SH, Yoo KH, et al. Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma. Bone Marrow Transplant, 2007 Jul;40( 1 ) : 37-45. 被引量:1
  • 9Schmidt ML, Lal A, Seeger RC, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children' s Cancer Group Study. J Clin Oncol, 2005 Sep 20 ;23 (27) :6474-6480. 被引量:1
  • 10George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol, 2005 Sep 20;23(27) :6466-6473. 被引量:1

共引文献9

同被引文献50

  • 1汤静燕,潘慈,陈静,徐敏,薛惠良,顾龙君,董茹,叶辉,周敏,王耀平.45例儿童神经母细胞瘤预后因素分析[J].中华儿科杂志,2006,44(10):770-773. 被引量:21
  • 2王家祥,张蛟,刘秋亮,王利,范应中,余捷凯,郑树.基于支持向量机对肾母细胞瘤患者血清蛋白质标记物的检测分析[J].中华医学杂志,2006,86(42):2982-2985. 被引量:8
  • 3黄钢,刘剑帆,徐学政,李林勤.新辅助化疗治疗儿童骨肉瘤[J].医学临床研究,2007,24(3):423-425. 被引量:4
  • 4Park JR, Scott JR, Stewart CF, et al, Pilot induction regimen incor- porating pharmacokineticaUy guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study[J].J Clin Oncol, 2011, 29(33): 4351-4357. 被引量:1
  • 5Castel V, TovarJA, Costa E, et al. The role of surgery in stage IV neuroblastoma[J].J Pediatr Surg, 2002, 37 (11): 1547-1578. 被引量:1
  • 6Bastian PJ, Fleischhack G, Zimmermann M, et al. The role ot com- plete surgical resection in stage IV Neuroblastoma[J]. WorldJ Urol, 2004, 22(4):257-260. 被引量:1
  • 7Bamias A, Aravantinos G, Kastriotis I, et al. Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/ cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT) : a risk adapted protocol of the Hellen- ic Cooperative Oncology Group[J]. Urol Oncol, 2011, 29(2): 189-193. 被引量:1
  • 8Daugaard G, Skoneczna I, Aass N, et al. A randomized phase Ⅲ study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-ceU cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)[J]. Ann Oncol, 2011, 22(5): 1054-1061. 被引量:1
  • 9Lorch A, Kleinhans A, Kramar A. et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized tri- al[J].J Clin Oncol, 2012, 30(8): 800-805. 被引量:1
  • 10Cairo MS, Sposto R, Gerrard M, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in childreix and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study[J]. J Clin Oncol, 2012, 30(4): 387-393. 被引量:1

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部